Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.55 |
| ▸ | FADS1 | O60427 | 6/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269334 | 0.80 | FADS1 (0.39) | HTR6FADS1ROCK2ROCK1 | |
| SCHEMBL9016279 | 0.80 | FADS1 (0.79) | HTR6FADS1ROCK2ROCK1HSD11B1 | |
| SCHEMBL1269516 | 0.79 | GRM2 (0.67) | GRM2 | |
| SCHEMBL1269301 | 0.77 | GRM2 (0.71) | GRM2 | |
| SCHEMBL1268264 | 0.77 | GRM2 (0.51) | GRM2 | |
| SCHEMBL1269230 | 0.75 | HTR6 (0.44) | HTR6FADS1ROCK2ROCK1HSD11B1 | |
| SCHEMBL1269233 | 0.75 | HTR6 (0.55) | HTR6ROCK2ROCK1 | |
| SCHEMBL1269318 | 0.74 | GRM2 (0.51) | GRM2 | |
| SCHEMBL5785493 | 0.73 | FADS1 (0.65) | HTR6FADS1ROCK2ROCK1HSD11B1 | |
| SCHEMBL7775135 | 0.73 | FADS1 (0.65) | HTR6FADS1ROCK2ROCK1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | HTR6 3561/4885FADS1 3210/4885ROCK2 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.